Hub : Traits :

Taking other prescription medications

175 significantly associated models · 38 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	113608257	115152814	4	1	4.4e-09	2.6e-16	2.0e-09	46	BCL2L15
2	1	206559362	207773991	1	1	2.0e-07	6.2e-06	9.5e-02	86	IL24
3	2	102680184	103216820	1	1	4.6e-08	1.9e-07	1.6e-02	79	IL1RL1
4	3	48702606	51043528	17	1	2.5e-12	2.8e-11	4.7e-01	99	MST1R
5	4	103091730	104503936	1	1	1.4e-07	1.5e-07	1.3e-06	15	CISD2
6	6	166651581	167841508	2	1	5.9e-08	1.8e-07	4.4e-01	98	RNASET2
7	9	91279481	92726464	1	1	1.7e-07	2.3e-06	2.6e-02	78	SEMA4D
8	10	5027660	6504126	1	1	2.7e-09	1.7e-07	1.4e-01	92	FAM208B
9	12	111154626	113517494	3	1	6.3e-10	4.8e-16	7.2e-08	56	SH2B3
10	14	74424938	76089054	3	1	7.9e-10	1.4e-10	1.0e+00	100	DLST
11	17	37644854	39048774	2	1	5.8e-08	9.7e-07	3.8e-01	97	RAPGEFL1
12	17	47119135	47685050	1	1	3.0e-09	1.2e-08	3.0e-01	97	ZNF652
13	20	30451844	30992291	1	1	2.7e-07	1.3e-07	1.0e+00	100	TM9SF4

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Blood Eosinophil Count	31.35	6	5	11.1	0.70	1.2e-01	DLST FAM208B IL1RL1 MST1R SH2B3 ZNF652
Hypothyroidism (self reported)	24.62	5	4	8.9	0.95	1.4e-02	BCL2L15 FAM208B IL24 RNASET2 SH2B3
Blood White Count	24.23	7	3	6.7	0.57	1.8e-01	BCL2L15 IL1RL1 MST1R RAPGEFL1 RNASET2 SH2B3 ZNF652
Respiratory disease	23.27	5	3	6.7	0.75	1.4e-01	FAM208B IL1RL1 MST1R RAPGEFL1 ZNF652
Asthma (self-reported)	22.13	4	3	6.7	0.90	1.0e-01	IL1RL1 MST1R RAPGEFL1 ZNF652
Asthma	21.87	4	3	6.7	0.90	1.0e-01	IL1RL1 MST1R RAPGEFL1 ZNF652
Hypothyroidism/myxoedema (self-reported)	20.40	4	4	8.9	1.00	3.9e-03	BCL2L15 FAM208B RNASET2 SH2B3
Allergy	19.97	4	3	6.7	-0.83	1.7e-01	CISD2 IL1RL1 RAPGEFL1 ZNF652
Medication: Levothyroxine sodium	17.84	4	4	8.9	0.99	7.1e-03	BCL2L15 FAM208B RNASET2 SH2B3
Allergy or Eczema	15.09	4	3	6.7	0.49	5.1e-01	IL1RL1 RAPGEFL1 SH2B3 ZNF652
Hayfever, allergic rhinitis or eczema	13.77	3	3	6.7	0.00	1.0e+00	IL1RL1 RAPGEFL1 ZNF652
Number of treatments/medications taken	13.53	9	6	13.3	0.99	1.3e-07	BCL2L15 CISD2 DLST FAM208B MST1R RNASET2 SH2B3 TM9SF4 ZNF652
Wheeze or whistling in the chest in last year	12.63	5	3	6.7	0.94	2.0e-02	DLST IL1RL1 MST1R RAPGEFL1 ZNF652
Rheumatoid Arthritis	12.34	3	1	2.2	0.00	1.0e+00	BCL2L15 FAM208B SH2B3
Number of self-reported non-cancer illnesses	11.17	9	3	6.7	0.97	9.4e-06	CISD2 DLST FAM208B IL1RL1 MST1R RAPGEFL1 RNASET2 SH2B3 ZNF652
Medication: Ventolin 100micrograms inhaler	10.44	4	2	4.4	0.94	6.1e-02	IL1RL1 MST1R RAPGEFL1 ZNF652
Long-standing illness, disability or infirmity	9.22	6	1	2.2	1.00	9.9e-07	BCL2L15 FAM208B IL24 RNASET2 TM9SF4 ZNF652
Irritable Bowel Disease (IBD)	8.81	4	3	6.7	-0.29	7.1e-01	MST1R RAPGEFL1 RNASET2 TM9SF4
Crohns Disease (2017)	7.92	5	3	6.7	-0.20	7.4e-01	BCL2L15 MST1R RAPGEFL1 RNASET2 TM9SF4
Diastolic blood pressure, automated reading	7.41	4	3	6.7	0.84	1.6e-01	DLST MST1R SH2B3 ZNF652
Crohns Disease (2012)	6.73	3	3	6.7	0.00	1.0e+00	MST1R RAPGEFL1 RNASET2
Ulcerative Colitis (UC)	6.61	2	2	4.4	0.00	1.0e+00	MST1R RAPGEFL1
Hayfever/allergic rhinitis (self-reported)	6.56	2	1	2.2	0.00	1.0e+00	IL1RL1 RAPGEFL1
Medication: Blood pressure	6.53	4	2	4.4	0.99	8.0e-03	CISD2 SH2B3 TM9SF4 ZNF652
Cardiovascular Disease	6.50	4	3	6.7	0.97	2.7e-02	CISD2 SH2B3 TM9SF4 ZNF652
Vascular/heart problems diagnosed by doctor	6.44	4	3	6.7	-0.97	2.7e-02	CISD2 SH2B3 TM9SF4 ZNF652
Overall health rating	6.40	4	2	4.4	0.98	2.2e-02	BCL2L15 MST1R TM9SF4 ZNF652
Primary Biliary Cirrhosis	6.37	3	2	4.4	0.00	1.0e+00	CISD2 RAPGEFL1 SH2B3
Age at First Birth	5.87	2	1	2.2	0.00	1.0e+00	MST1R ZNF652
Medication for cholesterol	5.83	3	1	2.2	0.00	1.0e+00	CISD2 DLST SH2B3
Medication for cholesterol, blood pressure or diabetes	5.68	5	1	2.2	-0.99	1.8e-03	CISD2 MST1R SH2B3 TM9SF4 ZNF652
Medication: Atenolol	5.56	2	1	2.2	0.00	1.0e+00	IL1RL1 SH2B3
High blood pressure	5.45	3	3	6.7	0.00	1.0e+00	CISD2 SH2B3 ZNF652
Systolic Blood Pressure	5.22	3	3	6.7	0.00	1.0e+00	DLST SH2B3 ZNF652
Ulcerative Colitis	5.16	2	2	4.4	0.00	1.0e+00	MST1R RAPGEFL1
Hypertension (Self-reported)	5.14	3	3	6.7	0.00	1.0e+00	CISD2 SH2B3 ZNF652
Medication: Seretide 50 evohaler	5.08	3	0	0.0	0.00	1.0e+00	IL1RL1 MST1R ZNF652
Qualifications: College or University degree	5.01	1	1	2.2	0.00	1.0e+00	MST1R
Diabetes diagnosed by doctor	4.97	3	0	0.0	0.00	1.0e+00	CISD2 IL24 MST1R
Heart attack/myocardial infarction (self-reported)	4.84	2	0	0.0	0.00	1.0e+00	SH2B3 ZNF652
Heart attack	4.72	2	0	0.0	0.00	1.0e+00	SH2B3 ZNF652
Qualifications: A levels/AS levels or equivalent	4.65	1	1	2.2	0.00	1.0e+00	MST1R
Chest pain or discomfort	4.54	2	0	0.0	0.00	1.0e+00	IL1RL1 RAPGEFL1
Age at last live birth	4.50	1	1	2.2	0.00	1.0e+00	MST1R
Leg fat percentage (left)	4.43	3	2	4.4	0.00	1.0e+00	DLST MST1R SEMA4D
Fed-up feelings	4.42	3	3	6.7	0.00	1.0e+00	DLST MST1R SH2B3
Diabetes (self-reported)	4.42	2	0	0.0	0.00	1.0e+00	CISD2 MST1R
Father's age at death	4.36	2	1	2.2	0.00	1.0e+00	MST1R SH2B3
Medication for pain relief, constipation, heartburn	4.36	2	0	0.0	0.00	1.0e+00	CISD2 DLST
Medication: Blood pressure	4.34	4	1	2.2	0.96	3.6e-02	CISD2 DLST SH2B3 ZNF652
Leg fat percentage (right)	4.31	3	2	4.4	0.00	1.0e+00	DLST MST1R SEMA4D
Body mass index (BMI)	4.28	2	1	2.2	0.00	1.0e+00	MST1R SEMA4D
Age at first live birth	4.26	1	1	2.2	0.00	1.0e+00	MST1R
Loneliness, isolation	4.25	3	0	0.0	0.00	1.0e+00	MST1R RNASET2 SH2B3
Impedance of arm (left)	4.21	5	3	6.7	-0.43	4.7e-01	CISD2 MST1R RAPGEFL1 SH2B3 ZNF652
Medication: Metformin	4.14	1	0	0.0	0.00	1.0e+00	CISD2
Medication: Aspirin	4.12	1	0	0.0	0.00	1.0e+00	SH2B3
Illnesses of siblings	4.06	1	0	0.0	0.00	1.0e+00	SH2B3
Leg fat mass (left)	4.05	2	1	2.2	0.00	1.0e+00	MST1R SEMA4D
Impedance of arm (right)	4.04	5	2	4.4	-0.43	4.6e-01	CISD2 MST1R RAPGEFL1 SH2B3 ZNF652
Leg fat mass (right)	3.99	2	1	2.2	0.00	1.0e+00	MST1R SEMA4D
Intelligence (Savage-Jansen 2018)	3.96	1	1	2.2	0.00	1.0e+00	MST1R
Coronary Artery Disease (CAD)	3.91	2	0	0.0	0.00	1.0e+00	MST1R SH2B3
Depressed Affect (Nagel 2018)	3.90	3	1	2.2	0.00	1.0e+00	DLST MST1R SH2B3
BMI	3.90	3	1	2.2	0.00	1.0e+00	MST1R SEMA4D ZNF652
Birth weight of first child	3.89	1	1	2.2	0.00	1.0e+00	SH2B3
Mood swings	3.77	2	1	2.2	0.00	1.0e+00	DLST MST1R
Impedance of whole body	3.73	3	2	4.4	0.00	1.0e+00	CISD2 MST1R ZNF652
Exposure to tobacco smoke outside home	3.68	2	0	0.0	0.00	1.0e+00	MST1R SH2B3
Miserableness	3.67	2	1	2.2	0.00	1.0e+00	MST1R RAPGEFL1
Lung FEV1/FVC ratio	3.66	5	4	8.9	-0.99	1.6e-03	DLST IL1RL1 RAPGEFL1 TM9SF4 ZNF652
Mean time to correctly identify matches	3.59	1	1	2.2	0.00	1.0e+00	SH2B3
Verbal and Numeric Reasoning (VNR)	3.55	1	1	2.2	0.00	1.0e+00	MST1R
Fluid intelligence score	3.51	1	1	2.2	0.00	1.0e+00	MST1R
Pain experienced in last month	3.48	3	1	2.2	0.00	1.0e+00	MST1R SH2B3 TM9SF4
Neuroticism	3.46	2	1	2.2	0.00	1.0e+00	DLST MST1R
Angina	3.44	1	1	2.2	0.00	1.0e+00	ZNF652
Systolic blood pressure, automated reading	3.41	2	1	2.2	0.00	1.0e+00	DLST SH2B3
Financial situation satisfaction	3.35	1	0	0.0	0.00	1.0e+00	MST1R
Whole body fat mass	3.34	2	1	2.2	0.00	1.0e+00	MST1R SEMA4D
Body fat percentage	3.31	3	2	4.4	0.00	1.0e+00	DLST MST1R SEMA4D
Type 2 Diabetes (T2D) (2018)	3.28	2	0	0.0	0.00	1.0e+00	MST1R SH2B3
Reaction Time	3.24	1	1	2.2	0.00	1.0e+00	SH2B3
Arm fat mass (left)	3.24	2	1	2.2	0.00	1.0e+00	MST1R SEMA4D
Arm fat mass (right)	3.23	1	1	2.2	0.00	1.0e+00	MST1R
Past tobacco smoking	3.22	3	0	0.0	0.00	1.0e+00	DLST SH2B3 ZNF652
Qualifications: NVQ or HND or HNC or equivalent	3.22	1	0	0.0	0.00	1.0e+00	MST1R
Neuroticism score	3.20	2	1	2.2	0.00	1.0e+00	DLST MST1R
Neuroticism (Nagel 2018)	3.19	2	1	2.2	0.00	1.0e+00	DLST RNASET2
HDL Cholesterol	3.19	2	1	2.2	0.00	1.0e+00	MST1R RAPGEFL1
Qualifications: None of the above	3.13	1	1	2.2	0.00	1.0e+00	MST1R
Worry (Nagel 2018)	3.12	1	1	2.2	0.00	1.0e+00	DLST
Gout (self-reported)	3.12	1	0	0.0	0.00	1.0e+00	SH2B3
Ever highly irritable/argumentative for 2 days	3.10	1	1	2.2	0.00	1.0e+00	MST1R
Smoking status: Previous	2.98	2	0	0.0	0.00	1.0e+00	DLST SH2B3
Impedance of leg (left)	2.96	3	2	4.4	0.00	1.0e+00	DLST MST1R ZNF652
Medication: Ramipril	2.96	1	0	0.0	0.00	1.0e+00	ZNF652
Arm fat percentage (left)	2.95	3	1	2.2	0.00	1.0e+00	DLST MST1R SEMA4D
Ever unenthusiastic/disinterested for a whole week	2.94	1	0	0.0	0.00	1.0e+00	DLST
Age started oral contraceptive pill	2.94	2	0	0.0	0.00	1.0e+00	MST1R ZNF652
Waist circumference	2.93	2	1	2.2	0.00	1.0e+00	MST1R SEMA4D
Impedance of leg (right)	2.91	3	2	4.4	0.00	1.0e+00	DLST MST1R ZNF652
Angina (self-reported)	2.91	1	0	0.0	0.00	1.0e+00	ZNF652
Arm fat percentage (right)	2.90	3	1	2.2	0.00	1.0e+00	DLST MST1R SEMA4D
Alcohol intake versus 10 years previously	2.87	1	1	2.2	0.00	1.0e+00	MST1R
Medication: Gliclazide	2.83	1	0	0.0	0.00	1.0e+00	CISD2
Trunk fat percentage	2.81	3	1	2.2	0.00	1.0e+00	DLST MST1R SEMA4D
Trunk fat mass	2.78	2	1	2.2	0.00	1.0e+00	MST1R SEMA4D
Medication: Lisinopril	2.77	1	0	0.0	0.00	1.0e+00	SH2B3
Blood Platelet Count	2.75	4	2	4.4	-0.05	9.5e-01	DLST SEMA4D SH2B3 TM9SF4
Worrier / anxious feelings	2.73	2	1	2.2	0.00	1.0e+00	DLST TM9SF4
Number of live births	2.71	1	0	0.0	0.00	1.0e+00	MST1R
Qualifications: nursing, teaching	2.71	1	0	0.0	0.00	1.0e+00	MST1R
Mouth/teeth dental problems: Mouth ulcers	2.71	2	0	0.0	0.00	1.0e+00	RAPGEFL1 SH2B3
Medication: Bendroflumethiazide	2.70	1	0	0.0	0.00	1.0e+00	SH2B3
Mouth/teeth dental problems: Dentures	2.67	1	1	2.2	0.00	1.0e+00	MST1R
Weight	2.66	2	1	2.2	0.00	1.0e+00	MST1R SH2B3
Guilty feelings	2.65	1	0	0.0	0.00	1.0e+00	DLST
Illnesses of mother	2.64	1	0	0.0	0.00	1.0e+00	ZNF652
Chronic bronchitis/emphysema (mother)	2.64	1	0	0.0	0.00	1.0e+00	MST1R
High blood pressure (siblings)	2.61	1	0	0.0	0.00	1.0e+00	SH2B3
Emphysema/chronic bronchitis	2.57	1	0	0.0	0.00	1.0e+00	RAPGEFL1
Leg pain on walking	2.57	1	1	2.2	0.00	1.0e+00	MST1R
Ever smoked	2.55	2	0	0.0	0.00	1.0e+00	SH2B3 ZNF652
Medication: Allopurinol	2.53	1	0	0.0	0.00	1.0e+00	SH2B3
Health satisfaction	2.52	1	0	0.0	0.00	1.0e+00	MST1R
Frequency of tenseness / restlessness in last 2 weeks	2.51	1	0	0.0	0.00	1.0e+00	MST1R
Illnesses of father: Heart disease	2.50	1	0	0.0	0.00	1.0e+00	SH2B3
Arm fat-free mass (left)	2.50	2	2	4.4	0.00	1.0e+00	MST1R SH2B3
Nervous feelings	2.49	1	1	2.2	0.00	1.0e+00	DLST
Arm predicted mass (left)	2.48	2	2	4.4	0.00	1.0e+00	MST1R SH2B3
Medication: Omeprazole	2.45	1	0	0.0	0.00	1.0e+00	MST1R
Number of operations (self-reported)	2.45	1	0	0.0	0.00	1.0e+00	MST1R
Illnesses of father: High blood pressure	2.44	1	0	0.0	0.00	1.0e+00	SH2B3
Blood Red Count	2.43	2	1	2.2	0.00	1.0e+00	SH2B3 TM9SF4
Arm predicted mass (right)	2.43	2	2	4.4	0.00	1.0e+00	MST1R SH2B3
Arm fat-free mass (right)	2.36	2	2	4.4	0.00	1.0e+00	MST1R SH2B3
Had major operations	2.34	1	0	0.0	0.00	1.0e+00	ZNF652
Average weekly beer plus cider intake	2.33	1	1	2.2	0.00	1.0e+00	MST1R
Smoking Status	2.31	2	0	0.0	0.00	1.0e+00	TM9SF4 ZNF652
Medication: Co-codamol	2.27	1	0	0.0	0.00	1.0e+00	MST1R
Seen doctor (GP) for nerves, anxiety, tension or depression	2.22	1	0	0.0	0.00	1.0e+00	DLST
Ever had bowel cancer screening	2.17	1	0	0.0	0.00	1.0e+00	MST1R
Hip circumference	2.16	2	1	2.2	0.00	1.0e+00	MST1R SH2B3
Exposure to tobacco smoke at home	2.15	1	0	0.0	0.00	1.0e+00	MST1R
Comparative body size at age 10	2.13	1	1	2.2	0.00	1.0e+00	ZNF652
Suffer from 'nerves'	2.13	1	0	0.0	0.00	1.0e+00	DLST
Birth weight	2.10	1	1	2.2	0.00	1.0e+00	SH2B3
Alcohol intake frequency.	2.09	1	1	2.2	0.00	1.0e+00	MST1R
Neuroticism (2016)	2.08	1	0	0.0	0.00	1.0e+00	DLST
Breast Cancer	2.07	1	0	0.0	0.00	1.0e+00	BCL2L15
Qualifications: O levels/GCSEs or equivalent	2.06	1	0	0.0	0.00	1.0e+00	MST1R
Maternal smoking around birth	2.05	1	0	0.0	0.00	1.0e+00	MST1R
Knee pain experienced in last month	2.05	1	0	0.0	0.00	1.0e+00	MST1R
Qualifications: CSEs or equivalent	2.04	1	0	0.0	0.00	1.0e+00	MST1R
LDL Cholesterol	2.00	1	0	0.0	0.00	1.0e+00	SH2B3
Basal metabolic rate	2.00	2	2	4.4	0.00	1.0e+00	MST1R SH2B3
Tense / 'highly strung'	1.90	1	0	0.0	0.00	1.0e+00	DLST
Pain type(s) experienced in last month: Hip pain	1.89	1	0	0.0	0.00	1.0e+00	TM9SF4
Whole body water mass	1.84	3	2	4.4	0.00	1.0e+00	DLST MST1R SH2B3
Whole body fat-free mass	1.80	3	2	4.4	0.00	1.0e+00	DLST MST1R SH2B3
Sensitivity / hurt feelings	1.76	1	0	0.0	0.00	1.0e+00	CISD2
Leg fat-free mass (left)	1.76	2	1	2.2	0.00	1.0e+00	MST1R SH2B3
Leg predicted mass (left)	1.76	2	1	2.2	0.00	1.0e+00	MST1R SH2B3
Age when periods started (menarche)	1.75	1	0	0.0	0.00	1.0e+00	MST1R
Illnesses of father: None of the above (group 1)	1.73	1	0	0.0	0.00	1.0e+00	SH2B3
Trunk fat-free mass	1.72	3	2	4.4	0.00	1.0e+00	DLST MST1R SH2B3
Prospective memory result	1.70	1	0	0.0	0.00	1.0e+00	MST1R
Trunk predicted mass	1.70	3	2	4.4	0.00	1.0e+00	DLST MST1R SH2B3
Heel bone mineral density (BMD) T-score, automated (left)	1.69	1	0	0.0	0.00	1.0e+00	MST1R
Leg fat-free mass (right)	1.66	3	1	2.2	0.00	1.0e+00	DLST MST1R SH2B3
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.65	1	0	0.0	0.00	1.0e+00	RAPGEFL1
Leg predicted mass (right)	1.65	3	1	2.2	0.00	1.0e+00	DLST MST1R SH2B3
Blood clot in the leg (DVT)	1.62	1	0	0.0	0.00	1.0e+00	SH2B3
Osteoarthritis (self-reported)	1.57	1	0	0.0	0.00	1.0e+00	MST1R
Pulse rate, automated reading	1.52	1	0	0.0	0.00	1.0e+00	MST1R
Irritability	1.52	1	0	0.0	0.00	1.0e+00	DLST
Heel bone mineral density (BMD) T-score, automated (right)	1.46	1	0	0.0	0.00	1.0e+00	MST1R
Forced expiratory volume in 1-second (FEV1)	1.39	1	0	0.0	0.00	1.0e+00	MST1R
Forced expiratory volume in 1-second (FEV1), Best measure	1.36	1	0	0.0	0.00	1.0e+00	MST1R
Comparative height size at age 10	1.36	2	1	2.2	0.00	1.0e+00	DLST SH2B3
Lung FVC	1.31	3	0	0.0	0.00	1.0e+00	MST1R SH2B3 TM9SF4
Standing height	1.14	3	3	6.7	0.00	1.0e+00	DLST SH2B3 ZNF652
Height	1.07	3	3	6.7	0.00	1.0e+00	DLST SH2B3 ZNF652
Heel T-Score	1.05	1	1	2.2	0.00	1.0e+00	MST1R
Hand grip strength (left)	1.01	1	0	0.0	0.00	1.0e+00	DLST
Forced vital capacity (FVC), Best measure	0.79	1	0	0.0	0.00	1.0e+00	MST1R
Forced vital capacity (FVC)	0.78	1	0	0.0	0.00	1.0e+00	MST1R
Sitting height	0.72	1	1	2.2	0.00	1.0e+00	ZNF652
Tanning	0.63	3	1	2.2	0.00	1.0e+00	DLST SH2B3 TM9SF4
Hair Pigment	0.23	1	1	2.2	0.00	1.0e+00	SH2B3

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Cerebellar Hemisphere	4	0.269	1.7
GTEx	Brain Cerebellum	4	0.202	1.7
GTEx	Breast Mammary Tissue	3	0.152	1.7
GTEx	Skin Not Sun Exposed Suprapubic	5	0.203	1.7
GTEx	Skin Sun Exposed Lower leg	8	0.220	1.7
GTEx	Small Intestine Terminal Ileum	1	0.217	1.7
GTEx	Adipose Subcutaneous	2	0.057	1.6
GTEx	Artery Aorta	3	0.101	1.6
GTEx	Artery Tibial	5	0.133	1.6
GTEx	Brain Caudate basal ganglia	2	0.217	1.6
GTEx	Brain Cortex	2	0.193	1.6
GTEx	Brain Frontal Cortex BA9	2	0.216	1.6
GTEx	Cells EBV-transformed lymphocytes	1	0.070	1.6
GTEx	Cells Transformed fibroblasts	3	0.071	1.6
GTEx	Colon Transverse	3	0.145	1.6
GTEx	Esophagus Gastroesophageal Junction	2	0.138	1.6
GTEx	Esophagus Mucosa	5	0.151	1.6
GTEx	Esophagus Muscularis	2	0.062	1.6
GTEx	Heart Atrial Appendage	3	0.190	1.6
GTEx	Lung	5	0.174	1.6
GTEx	Muscle Skeletal	1	0.035	1.6
GTEx	Pancreas	1	0.061	1.6
GTEx	Pituitary	1	0.090	1.6
GTEx	Spleen	3	0.213	1.6
GTEx	Thyroid	4	0.100	1.6
GTEx	Uterus	0	0.000	1.6
GTEx	Vagina	1	0.157	1.6
GTEx	Whole Blood	2	0.100	1.6
NTR	Blood	4	0.167	1.6
CommonMind	Brain Pre-frontal Cortex	5	0.093	1.6
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.146	1.6
The Cancer Genome Atlas	Lung Adenocarcinoma	4	0.136	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	2	0.120	1.6
GTEx	Adipose Visceral Omentum	2	0.098	1.5
GTEx	Adrenal Gland	1	0.069	1.5
GTEx	Artery Coronary	1	0.085	1.5
GTEx	Brain Hippocampus	0	0.000	1.5
GTEx	Brain Hypothalamus	0	0.000	1.5
GTEx	Brain Nucleus accumbens basal ganglia	2	0.231	1.5
GTEx	Brain Putamen basal ganglia	1	0.160	1.5
GTEx	Breast Mammary Tissue (Female)	1	0.061	1.5
GTEx	Colon Sigmoid	2	0.137	1.5
GTEx	Heart Left Ventricle	2	0.131	1.5
GTEx	Liver	1	0.139	1.5
GTEx	Nerve Tibial	3	0.069	1.5
GTEx	Ovary	0	0.000	1.5
GTEx	Prostate	1	0.120	1.5
GTEx	Stomach	2	0.138	1.5
GTEx	Testis	4	0.127	1.5
METSIM	Adipose	3	0.065	1.5
ROSMAP	Brain Pre-frontal Cortex	5	0.114	1.5
YFS	Blood	4	0.087	1.5
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	1	0.060	1.5
The Cancer Genome Atlas	Breast Invasive Carcinoma	5	0.113	1.5
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	1	0.091	1.5
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	1.5
The Cancer Genome Atlas	Glioblastoma Multiforme	2	0.196	1.5
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	2	0.073	1.5
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	6	0.146	1.5
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	3	0.146	1.5
The Cancer Genome Atlas	Brain Lower Grade Glioma	7	0.163	1.5
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	2	0.080	1.5
The Cancer Genome Atlas	Prostate Adenocarcinoma	3	0.065	1.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	2	0.119	1.5
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.5
The Cancer Genome Atlas	Thyroid Carcinoma	6	0.116	1.5
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.5
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.4
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.4
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	1	0.063	1.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	1	0.075	1.4
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.4
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.4
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.4